Cited 22 times in

Radiation Therapy-First Strategy After Surgery With or Without Adjuvant Chemotherapy in Stage IIIA-N2 Non-Small Cell Lung Cancer

DC Field Value Language
dc.contributor.authorLee, HW-
dc.contributor.authorNoh, OK-
dc.contributor.authorOh, YT-
dc.contributor.authorChoi, JH-
dc.contributor.authorChun, M-
dc.contributor.authorKim, HI-
dc.contributor.authorHeo, J-
dc.contributor.authorAhn, MS-
dc.contributor.authorPark, SY-
dc.contributor.authorPark, RW-
dc.contributor.authorYoon, D-
dc.date.accessioned2018-05-04T00:26:17Z-
dc.date.available2018-05-04T00:26:17Z-
dc.date.issued2016-
dc.identifier.issn0360-3016-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/15112-
dc.description.abstractPURPOSE: Postoperative radiation therapy (PORT) and postoperative chemotherapy (POCT) can be administered as adjuvant therapies in patients with non-small cell lung cancer (NSCLC). The aim of this study was to present the clinical outcomes in patients treated with PORT-first with or without subsequent POCT in stage IIIA-N2 NSCLC. METHODS AND MATERIALS: From January 2002 to November 2014, the conditions of 105 patients with stage IIIA-N2 NSCLC who received PORT-first with or without subsequent POCT were analyzed. PORT was initiated within 4 to 6 weeks after surgical resection. Platinum-based POCT was administered 3 to 4 weeks after the completion of PORT. We analyzed the outcomes and the clinical factors affecting survival. RESULTS: Of 105 patients, 43 (41.0%) received POCT with a median of 4 cycles (range, 2-6 cycles). The follow-up times ranged from 3 to 123 months (median, 30 months), and the 5-year overall survival (OS) was 40.2%. The 5-year OS of patients treated with PORT and POCT was significantly higher than that of patients with PORT (61.3% vs 29.2%, P<.001). The significant prognostic factors affecting OS were the use of POCT (hazard ratio [HR] = 0.453, P=.036) and type of surgery (pneumonectomy/lobectomy: HR = 2.845, P<.001). CONCLUSIONS: PORT-first strategy after surgery appeared not to compromise the clinical outcomes in the treatment of stage IIIA-N2 NSCLC. The benefit of POCT on OS was preserved even in the PORT-first setting. Further studies are warranted to compare the sequencing of PORT and POCT, guaranteeing the proper use of POCT.-
dc.language.isoen-
dc.subject.MESHAdenocarcinoma/drug therapy-
dc.subject.MESHAdenocarcinoma/mortality-
dc.subject.MESHAdenocarcinoma/pathology-
dc.subject.MESHAdenocarcinoma/radiotherapy-
dc.subject.MESHAdenocarcinoma/surgery-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHCarcinoma, Non-Small-Cell Lung/drug therapy-
dc.subject.MESHCarcinoma, Non-Small-Cell Lung/mortality-
dc.subject.MESHCarcinoma, Non-Small-Cell Lung/pathology-
dc.subject.MESHCarcinoma, Non-Small-Cell Lung/radiotherapy-
dc.subject.MESHCarcinoma, Non-Small-Cell Lung/surgery-
dc.subject.MESHCarcinoma, Squamous Cell/drug therapy-
dc.subject.MESHCarcinoma, Squamous Cell/mortality-
dc.subject.MESHCarcinoma, Squamous Cell/pathology-
dc.subject.MESHCarcinoma, Squamous Cell/radiotherapy-
dc.subject.MESHCarcinoma, Squamous Cell/surgery-
dc.subject.MESHChemotherapy, Adjuvant-
dc.subject.MESHFemale-
dc.subject.MESHFollow-Up Studies-
dc.subject.MESHHumans-
dc.subject.MESHLung Neoplasms/drug therapy-
dc.subject.MESHLung Neoplasms/mortality-
dc.subject.MESHLung Neoplasms/pathology-
dc.subject.MESHLung Neoplasms/radiotherapy-
dc.subject.MESHLung Neoplasms/surgery-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHPostoperative Period-
dc.subject.MESHRadiotherapy, Adjuvant/mortality-
dc.subject.MESHRadiotherapy, Conformal-
dc.subject.MESHTime Factors-
dc.subject.MESHTreatment Outcome-
dc.titleRadiation Therapy-First Strategy After Surgery With or Without Adjuvant Chemotherapy in Stage IIIA-N2 Non-Small Cell Lung Cancer-
dc.typeArticle-
dc.identifier.pmid26867891-
dc.contributor.affiliatedAuthor이, 현우-
dc.contributor.affiliatedAuthor노, 오규-
dc.contributor.affiliatedAuthor오, 영택-
dc.contributor.affiliatedAuthor최, 진혁-
dc.contributor.affiliatedAuthor전, 미선-
dc.contributor.affiliatedAuthor허, 재성-
dc.contributor.affiliatedAuthor안, 미선-
dc.contributor.affiliatedAuthor박, 성용-
dc.contributor.affiliatedAuthor박, 래웅-
dc.contributor.affiliatedAuthor윤, 덕용-
dc.type.localJournal Papers-
dc.identifier.doi10.1016/j.ijrobp.2015.11.020-
dc.citation.titleInternational journal of radiation oncology, biology, physics-
dc.citation.volume94-
dc.citation.number3-
dc.citation.date2016-
dc.citation.startPage621-
dc.citation.endPage627-
dc.identifier.bibliographicCitationInternational journal of radiation oncology, biology, physics, 94(3). : 621-627, 2016-
dc.embargo.liftdate9999-12-31-
dc.embargo.terms9999-12-31-
dc.identifier.eissn1879-355X-
dc.relation.journalidJ003603016-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Hematology-Oncology
Journal Papers > School of Medicine / Graduate School of Medicine > Radiation Oncology
Journal Papers > School of Medicine / Graduate School of Medicine > Thoracic & Cardiovascular Surgery
Journal Papers > School of Medicine / Graduate School of Medicine > Biomedical Informatics
Files in This Item:

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse